These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 17686376

  • 1. The vasodilatory beta-blockers.
    Pedersen ME, Cockcroft JR.
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [Abstract] [Full Text] [Related]

  • 2. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
    Bakris G.
    J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898
    [Abstract] [Full Text] [Related]

  • 3. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
    Drugs; 2010 May; 70(1):41-56. PubMed ID: 20030424
    [Abstract] [Full Text] [Related]

  • 4. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H, Lavie CJ, Ventura HO.
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [Abstract] [Full Text] [Related]

  • 5. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL, Saseen JJ.
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [Abstract] [Full Text] [Related]

  • 6. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J, Barbosa L, Silva JA, Bertoquini S.
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [Abstract] [Full Text] [Related]

  • 7. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E, Rizzoni D.
    Drugs; 2007 Oct; 67(8):1097-107. PubMed ID: 17521213
    [Abstract] [Full Text] [Related]

  • 8. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
    Pedersen ME, Cockcroft JR.
    Curr Opin Cardiol; 2009 Jul; 24(4):325-32. PubMed ID: 19417638
    [Abstract] [Full Text] [Related]

  • 9. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, Galdames K, Noriega V, Miranda HF.
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [Abstract] [Full Text] [Related]

  • 10. Realities of newer beta-blockers for the management of hypertension.
    Manrique C, Giles TD, Ferdinand KC, Sowers JR.
    J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633
    [Abstract] [Full Text] [Related]

  • 11. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).
    Shah NK, Smith SM, Nichols WW, Lo MC, Ashfaq U, Satish P, Johnson JA, Epstein BJ.
    J Clin Hypertens (Greenwich); 2011 Dec; 13(12):917-24. PubMed ID: 22142351
    [Abstract] [Full Text] [Related]

  • 12. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA.
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [Abstract] [Full Text] [Related]

  • 13. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
    Mahmud A, Feely J.
    Am J Hypertens; 2008 Jun; 21(6):663-7. PubMed ID: 18437130
    [Abstract] [Full Text] [Related]

  • 14. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
    Black HR, Greenberg BH, Weber MA.
    Am J Med; 2010 Nov; 123(11):S2. PubMed ID: 21035578
    [Abstract] [Full Text] [Related]

  • 15. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
    Fang Y, Nicol L, Harouki N, Monteil C, Wecker D, Debunne M, Bauer F, Lallemand F, Richard V, Thuillez C, Mulder P.
    J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
    [Abstract] [Full Text] [Related]

  • 16. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.
    Wehland M, Grosse J, Simonsen U, Infanger M, Bauer J, Grimm D.
    Curr Vasc Pharmacol; 2012 May; 10(3):378-90. PubMed ID: 22022769
    [Abstract] [Full Text] [Related]

  • 17. Acute effects of third generation β-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats.
    Bertera FM, Del Mauro JS, Lovera V, Chiappetta D, Polizio AH, Taira CA, Höcht C.
    Hypertens Res; 2013 Apr; 36(4):349-55. PubMed ID: 23364340
    [Abstract] [Full Text] [Related]

  • 18. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N, Lim PO, MacDonald TM.
    Circulation; 2001 Jul 31; 104(5):511-4. PubMed ID: 11479245
    [Abstract] [Full Text] [Related]

  • 19. Vasodilatory mechanisms of beta receptor blockade.
    Rath G, Balligand JL, Dessy C.
    Curr Hypertens Rep; 2012 Aug 31; 14(4):310-7. PubMed ID: 22639015
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits.
    de Nigris F, Mancini FP, Balestrieri ML, Byrns R, Fiorito C, Williams-Ignarro S, Palagiano A, Crimi E, Ignarro LJ, Napoli C.
    Nitric Oxide; 2008 Aug 31; 19(1):57-63. PubMed ID: 18435936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.